CARE
Cholesterol And Recurrent Events

Purpose 1) To investigate whether the reduction of plasma cholesterol is of clinical benefit in patients with established coronary artery disease with plasma total cholesterol < 240 mg/dl 2) To assess whether the favourable results of cholesterol lowering in previous trials apply to a wider population (including the elderly) and in women whose plasma total cholesterol has been lowered by pravastatin treatment, and to ascertain the effects on fatal CV disease and total mortality of cholesterol lowering by pravastatin References Sacks FM, et al & Braunwald E: Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991, 68:1436-1446. Sacks FM, et al & Braunwald E for the Cholesterol and Recurrent Events Trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009. Lewis SJ, Mitchell JS, East C, et al: Women in CARE have earlier and greater response to pravastatin post myocardial infarction. Circulation 1996, 94:#0069. Goldberg R, Sacks F, Howard B, et al: Diabetic response to pravastatin during the CARE Study. Circulation 1996, 94:#3159.

Apoio: Farmacêutica